Shots:

• Foundation Medicine acquires Lexent to accelerate the Foundation’s R&D strategy and expand its existing liquid biopsy platforms to advance cancer care for patients. The acquisition will boost Foundation Medicine’s capabilities to support adaptive clinical trial designs and accelerate therapeutic development in both early/ late-stage disease
• The addition of Lexent’s technology to Foundation’s portfolio of tissue and liquid biopsy platforms will focus on new approaches for developing targeted therapies from discovery research via clinical development
• Lexent 's monitoring platform is currently in development and based on low-pass WGS and DNA methylation analysis while Foundation Medicine plans to integrate WGS and methylation into new assay platforms for supporting treatment decision across all stages of the disease

Click here to read full press release/ article | Ref: Foundation Medicine | Image: Lexent